Opinion|Videos|August 5, 2024
Applying EHA 2024 Data to Switching and Sequencing Treatments for CLL & Impact of Toxicities
Experts analyze recent real-world evidence on treatment patterns, focusing on the strategies and outcomes of switching and sequencing therapies in chronic lymphocytic leukemia patients.
Advertisement
Episodes in this series
- Briefly comment on recent real world data regarding switching and sequencing to next line of therapy in patients with CLL. (
Pinilla-Ibarz, et al. EHA 2024. Abstract P697 ) - How do you interpret these data and how may they influence your overall treatment approach?
Advertisement
Related to this article
The top 5 OncLive TV videos of the week cover pancreatic cancer, gastric cancer, GIST, renal cell carcinoma, and chronic lymphocytic leukemia.
Advertisement
Advertisement
Trending on OncLive
1
Five Under 5: Top Oncology Videos for the Week of 8/31/26
2
FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer
3
B7-H4–Targeted ADCs Signal a New Frontier for Platinum-Resistant Ovarian and Endometrial Cancer
4
The OncFive: Top Oncology Articles for the Week of 8/30
5